Collagen Triple Helix Repeat Containing 1 Promotes Melanoma Cell Adhesion and Survival

Abstract

French

Background:

The extracellular protein collagen triple helix repeat containing 1 (CTHRC1) is aberrantly upregulated in melanoma and most human solid cancers. However, its role in cancer remains unknown.

Objective:

In this study, we investigated the functional impact of CTHRC1 on melanoma cells in vitro.

Methods:

Stable clones of cultured melanoma cells expressing different amounts of CTHRC1 protein were generated and evaluated to characterize their growth, survival, and attachment ability as well as their sensitivity to chemotherapy.

Results:

In cultured MMAN and MMRU melanoma cells, increased expression of CTHRC1 protein resulted in morphologic cell changes, enhanced cell adhesion to culture surfaces, increased cell proliferation, and decreased apoptosis. Furthermore, decreased CTHRC1 expression through antisense inhibition enhanced temozolomide sensitivity.

Conclusion:

CTHRC1 expression influences cellular processes, including cell adhesion and survival. Additionally, CTHRC1 inhibition may represent a potential method for decreasing melanoma resistance to conventional chemotherapy.

Get full access to this article

View all access options for this article.

References

Kimura

Kwan

Zhang

. CTHRC1 is a positive regulator of osteoblastic bone formation. PLoS One 2008;3:e3174, doi:10. 1016/j.bone.2009.01.059.

Pyagay

Heroult

Wang

. Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration. Circ Res 2005;96:261–8, doi:10.1161/01.RES.0000154262.07264.12.

LeClair

Durmus

Wang

. CTHRC1 is a novel inhibitor of transforming growth factor-beta signaling and neointimal lesion formation. Circ Res 2007;100:826–33, doi:10.1161/01.RES.0000260806.99307.72.

Durmus

LeClair

Park

. Expression analysis of the novel gene collagen triple helix repeat containing-1 (CTHRC1). Gene Expr Patterns 2006;6:935–40, doi:10.1016/j.modgep.2006.03.008.

LeClair

Wang

Benson

. Intracellular localization of CTHRC1 characterizes differentiated smooth muscle. Arterioscler Thromb Vasc Biol 2008;28:1332–8, doi:10.1161/ATVBAHA.108.166579.

Yamamoto

Nishimura

Misaki

. Cthrc1 selectively activates the planar cell polarity pathway of wnt signaling by stabilizing the wnt-receptor complex. Dev Cell 2008;15:23–36, doi:10.1016/j.devcel.2008.05.007.

Tang

Dai

. Aberrant expression of collagen triple helix repeat containing 1 in human solid cancers. Clin Cancer Res 2006;12:3716–22, doi:10.1158/1078-0432.CCR-06-0030.

Dvorak

Flier

Frank

. Tumors—wounds that do not heal—similarities between tumor stroma generation and wound-healing. N Engl J Med 1986;315:1650–9, doi:10.1056/NEJM198612253152606.

Coussens

Werb

. Inflammation and cancer. Nature 2002;420:860–7, doi:10.1038/nature01322.

10.

Beachy

Karhadkar

Berman

. Tissue repair and stem cell renewal in carcinogenesis. Nature 2004;432:324–31, doi:10.1038/nature03100.

11.

Zhou

Dai

Martinka

. Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 2005;124:1044–52, doi:10.1111/j.0022-202X.2005.23680.x.

12.

Turashvili

Bouchal

Baumforth

. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 2007;7:55, doi:10.1186/1471–2407-7-55.

13.

Augustine

Yoo

Potti

. Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res 2009;15:502–10, doi:10.1158/1078-0432.CCR-08-1916.

14.

Soengas

Lowe

. Apoptosis and melanoma chemoresistance. Oncogene 2003;22:3138–51, doi:10.1038/sj.onc.1206454.

15.

Fontijn

Adema

Bhakat

. O-6-Methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor-induced resistance against temozolomide in human melanoma cells. Mol Cancer Ther 2007;6:2807–15, doi:10.1158/1535-7163.MCT-07-0044.

16.

Spiro

Liu

Gerson

. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance. Forum (Genova) 2000;10:274–85.

17.

Dunehoo

Anderson

Majumdar

. Cell adhesion molecules for targeted drug delivery. J Pharm Sci 2006;95:1856–72, doi:10.1002/jps.20676.

18.

Schwartz

Horwitz

. Integrating adhesion, protrusion, and contraction during cell migration. Cell 2006;125:1223–5, doi:10.1016/j.cell.2006.06.015.

19.

Yamada

Miyamoto

. Integrin transmembrane signaling and cytoskeletal control. Curr Opin Cell Biol 1995;7:681–9, doi:10.1016/0955-0674(95)80110-3.

20.

Haass

Smalley

. Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res 2005;18:150–9, doi:10.1111/j.1600-0749.2005.00235.x.

21.

McGary

Lev

Bar-Eli

. Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther 2002;1:459–65.

22.

Tsuji

Kawada

Kai-Murozono

. Regulation of melanoma cell migration and invasion by laminin-5 and alpha3beta1 integrin (VLA-3). Clin Exp Metastasis 2002;19:127–34, doi:10.1023/A:1014573204062.

23.

Albini

. Tumor and endothelial cell invasion of basement membranes. The Matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol Res 1998;4:230–41, doi:10.1007/BF02905254.

24.

Albini

Benelli

Noonan

. The “chemoinvasion assay”: a tool to study tumor and endothelial cell invasion of basement membranes. Int J Dev Biol 2004;48:563–71, doi:10.1387/ijdb.041822aa.

25.

Huber

Kraut

Beug

. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005;17:548–58, doi:10.1016/j.ceb.2005.08.001.

26.

Quinones

Garcia-Castro

. Characterization of human melanoma cell lines according to their migratory properties in vitro. In Vitro Cell Dev Biol Anim 2004;40:35–42, doi:10.1290/1543-706X(2004)40<35:COHMCL>2.0.CO;2.